ETON vs. WVE, IMCR, ANIP, DYN, INDV, AMPH, ARDX, EVO, ETNB, and OCUL
Should you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include Wave Life Sciences (WVE), Immunocore (IMCR), ANI Pharmaceuticals (ANIP), Dyne Therapeutics (DYN), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Evotec (EVO), 89bio (ETNB), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.
Eton Pharmaceuticals vs.
Wave Life Sciences (NASDAQ:WVE) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
Wave Life Sciences presently has a consensus price target of $22.60, indicating a potential upside of 125.55%. Eton Pharmaceuticals has a consensus price target of $27.67, indicating a potential upside of 106.78%. Given Wave Life Sciences' higher probable upside, research analysts plainly believe Wave Life Sciences is more favorable than Eton Pharmaceuticals.
89.7% of Wave Life Sciences shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 29.1% of Wave Life Sciences shares are owned by company insiders. Comparatively, 14.9% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Eton Pharmaceuticals has a net margin of -15.81% compared to Wave Life Sciences' net margin of -66.50%. Eton Pharmaceuticals' return on equity of -36.29% beat Wave Life Sciences' return on equity.
In the previous week, Eton Pharmaceuticals had 9 more articles in the media than Wave Life Sciences. MarketBeat recorded 25 mentions for Eton Pharmaceuticals and 16 mentions for Wave Life Sciences. Wave Life Sciences' average media sentiment score of 0.99 beat Eton Pharmaceuticals' score of 0.57 indicating that Wave Life Sciences is being referred to more favorably in the media.
Wave Life Sciences received 268 more outperform votes than Eton Pharmaceuticals when rated by MarketBeat users. Likewise, 67.78% of users gave Wave Life Sciences an outperform vote while only 65.77% of users gave Eton Pharmaceuticals an outperform vote.
Wave Life Sciences has a beta of -1.04, meaning that its stock price is 204% less volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500.
Eton Pharmaceuticals has lower revenue, but higher earnings than Wave Life Sciences. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Wave Life Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Wave Life Sciences beats Eton Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Eton Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eton Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ETON) was last updated on 3/27/2025 by MarketBeat.com Staff
Buy ETON Stock Free ETON Stock Alerts